1. Hirayama S., Miida T. Small dense LDL: An emerging risk factor for cardiovascular disease // Clin. Chim. Acta. 2012. Vol. 24, N 414. P. 215-224. DOI:10.1016/j.cca.2012.09.010.
2. Mora S., Caulfield M.P., Wohlgemuth J. et al. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial // Circulation. 2015. Vol. 132, N 23. P. 2220-2229. DOI: 10.1161/CIRCULATIONAHA.115.016857.
3. Lawler P.R., Akinkuolie A.O., Chu A.Y. et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol // J. Am. Heart Assoc. 2017. Vol. 6, N 7. P. e005549. DOI: 10.1161/JAHA.117.005549.
4. Dallmeier D., Koening W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA?) and lipoprotein(a) (Lp(a) // Best. Pract. Res. Clin. Endocrnol. Metab. 2014. Vol. 28, N 3. P. 281-294. DOI: 10.1016/j.beem.2014.01.003.
5. Sniderman A.D., Williams K., Contois J.H. et al. A meta-analysis of low-demsity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk // Circ. Cardiovasc. Outcomes. 2011. N 4. P. 337-345.
6. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity // J. Lipid Res. 2002. Vol. 43, N 9. P. 1363-1379. DOI: 10.1194/jlr. R200004-JLR200September 2002.
7. Hoefner D.M., Hodel S.D., O’Brein J.F. et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System // Clin. Chem. 2001. Vol. 47, N 2. P. 266-274.
8. Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis // Circulation. 2004. Vol.109. P. III-2-III-7. DOI: org/10.1161/01.CIR.0000131511.50734.44.
9. Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL // Curr. Opin. Lipidol. 2014. Vol. 25, N 3. P. 221-226. DOI: 10.1097/MOL.0000000000000067.
10. Srisawasdi P., Vanavanan S., Rochanawutanon M. et al. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations // Clin. Biochem. 2013. Vol. 46, N 15. P. 1509-1515. DOI:10.1016/j.clinbiochem.2013.06.021.
11. Varbo A., Benn M., Nordestgaard B.G. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment // Pharmacol. Ther. 2014. Vol. 141, N 3. P. 358-367. DOI: 10.1016/j.pharmthera.2013.11.008.
12. El Harchaoui K., van der Steeg W.A., Stroes E.S. et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study // J. Am. Coll. Cardiol. 2007. Vol. 49, N 5. P. 547-553. DOI: 10.1016/j.jacc. 2006.09.043.
13. Рагино Ю.И. Мелкие плотные субфракции липопротеинов низкой плотности и атерогенез // Рос. кардиол. журн. 2004. № 4. С. 84-90.
14. Озерова И.Н., Перова Н.В., Метельская В.А. и др. Субфракционный спектр липопротеинов низких плотностей при разной степени стенозов коронарных артерий // Кардиоваскулярная терапия и профилактика. 2013. № 4. С. 16-20.
15. Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеросклерозом у мужчин среднего возраста, получавших терапию статинами // Кардиол. вестн. 2014. Т. 9, № 1. С. 68-76.
16. Oravec S., Dukat A., Gavornik P. et al. Atherogenic versus non-atherogenic lipoprotein profiles in healthy individuals. is there a need to change our approach to diagnosing dyslipidemia? // Curr. Med. Chem. 2014. Vol. 21, N 25. P. 2892-2901. DOI: 10.2174/0929867321666140303153048.
17. Superko H.R. Advanced lipoprotein testing and subfractionation are clinically useful // Circulation. 2009. Vol. 119, N 17. P. 2383-2395. DOI: 10.1161/CIRCULATIONAHA.108.809582.
18. Davidson M.H. Apolipoprotein measurements: is more widespread use clinically indicated? // Clin. Cardiol. 2009. Vol.32, N 9. P. 482-486. DOI:10.1002/clc.20559.
19. Kucera M., Oravec S., Hirnerova E. et al. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study // Angiology. 2014. Vol. 65, N 9. P. 794-799. DOI: 10.1177/0003319713507476.
20. Афанасьева О.И., Уткина Е.А., Вихрова Е.Б. и др. Наличие мелких плотных липопротеидов низкой плотности в сыворотке крови человека вызывает накопление холестерина моноцитоподобными клетками линии ТНР-1 // Атеросклероз и дислипидемии. 2018. Т. 30, № 1. С. 38-46.